



3D InSight™ Oncology Service Packs


Efficacy testing services with 3D tumor microtissues

- Proven, physiologically relevant tumor models for predicting compound efficacy
- Years of InSphero 3D culture expertise for rapid, reliable results
- Convenient service packages – 5, 10 and 20 compounds

Ready to start testing in 3D?

If you are ready to start testing compounds in 3D culture systems but lack time and resources, why not hand your project to our experienced team of 3D assay experts?

With 3D InSight™ Service Packs InSphero's scientists offer you a short-cut to obtaining highly valuable efficacy data using our easily scalable, high-throughput microtissue technology coupled with Promega's CellTiter-Glo® ATP assay.



Light-sheet microscopy (mDSLM) image of HepG2 3D microtissue. Image provided gratefully by Nariman Ansari, Francesco Pampaloni and Ernst H. Stelzer, Goethe University Frankfurt.


Advantages of 3D microtissue-based assays

- Co-culture models mimic xenografts more closely than 2D assays
- 3D spheroids mimic natural nutrient and oxygen gradients
- Tissue-specific expression of context-dependent proteins and enzymes
- Optimized Promega CellTiter-Glo® assay
- No bioartificial matrices

Advantages of 3D InSight™ Services

Responding to the demand for standardized, fast turnaround 3D-cell-based screening services, InSphero created 3D InSight™ Service Packs. These standard efficacy testing services are designed to give you the following advantages:

- Effortless outsourcing to quickly access valuable 3D assay data
- Conveniently benchmark 3D against your existing assay technology
- Experienced scientists help with results interpretation
- Reliable processes and protocols based on InSphero's market-leading experience
- Testing conducted by 3D-cell-culture experts in a certified ISO 9001 environment.



Determination of the IC50 value of an HCT-116-based 3D microtissue treated with various concentrations of staurosporine. Biochemical readout.

3D InSight™ - how does it work?

1. Tell us how many compounds you want to test:
5, 10 or 20
2. Tell us which 3D tumor model you want to test in, for example:

Single-cell-type microtissues	Dual-cell-type microtissues (with NIH3T3)
■ Colon cancer (HCT116)	■ HCT116:NIH3T3
■ Colon cancer (HT29)	■ DU145:NIH3T3
■ Prostate cancer (DU145)	■ SNB19:NIH3T3
■ Glioblastoma (SNB19)	■ HepG2:NIH3T3
■ Hepatocarcinoma (HepG2)	■ A498:NIH3T3
■ Kidney carcinoma (A498)	■ Breast cancer (MCF7:NIH3T3)
	■ A549:NIH3T3

Many more models are available on our website.

3. InSphero will test as follows:
 - 6 dilutions in quadruplicates
 - Incubation for 72h
 - ATP assay (Promega CellTiter-Glo®)
4. You receive:
 - A written report
 - A web-based presentation and discussion

Ordering information

Catalog #	Description
SP-01-001-00	3D InSight™ Oncology Service Pack 5 compounds
SP-01-002-00	3D InSight™ Oncology Service Pack 10 compounds
SP-01-003-00	3D InSight™ Oncology Service Pack 20 compounds

For pricing and details, visit us at www.insphero.com/services or contact our local branch offices and authorized distributors.



QR Code

IS-500-0012-01-A

CellTiter-Glo® is a registered trademark of Promega Corporation.

InSphero AG
Schlieren, Switzerland
☎ +41-44-515049-0

InSphero Inc.
Cambridge, MA, USA
☎ +1-800-779-7558

InSphero Europe GmbH
Waldshut, Germany
☎ +49-7751-3049665-0

info@insphero.com
www.insphero.com

Authorized Distributors
www.insphero.com/distributors

InSphero is ISO 9001:2008 certified
All rights reserved, © 2013 InSphero AG. 3D InSight™ and GravityPLUS™ are trademarks of InSphero AG. For life science research only. Not for use in diagnostic procedures.